Press "Enter" to skip to content

Diagnostic Radiopharmaceuticals & Contrast Media Market Outlook 2019 | Shows Industry Overview, Size, Share, Remarkable Growth Factors, Types, and Applications Forecast to 2024

Diagnostic

The “Diagnostic Radiopharmaceuticals & Contrast Media Market” research report 2019 delivers comprehensive information about the market ranging from the establishment to the predictable growth trend. Diagnostic Radiopharmaceuticals & Contrast Media market report provides brief analytical data of the market contenders globally using advanced methodological approaches, such as SWOT analysis, production chain, cost, sales margin, financial details, recent developments. Diagnostic Radiopharmaceuticals & Contrast Media market report also offers market competitors that includes detailed company profiles along with company product specifications.

Market Overview:

  • The global diagnostic radiopharmaceuticals and contrast media market is growing at a steady rate, due to factors, such as technological developments, increasing diagnostic applications in various diseases, government support, and rising cases of chronic diseases. Also, factors, such as shorter half-life of radiopharmaceuticals, stringent regulatory framework, and high capital investment, are expected to hinder the market growth.
  • The development in the minimally invasive therapeutic procedures has encouraged the usage of imaging equipment. This increase in the demand for image guidance has propelled the market. Additionally, medical imaging has witnessed numerous advancements in recent times. The emerging technologies help in enhancing the resolution and quality of the medical images, in turn, propelling the demand for contrast media and diagnostic radiopharmaceuticals. Rising cancer cost is another factor, which is impacting healthcare costs. The government is taking several initiatives for better cancer management. These initiatives are likely to affect the imaging industry, as they give the multinational companies a potential place to make significant investments.

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/13999529

    In Diagnostic Radiopharmaceuticals & Contrast Media Market Report, Following Companies Are Covered:

  • Bioclinica
  • Bio
  • Optronics Inc.
  • DATATRAK International Inc.
  • ERT Clinical
  • IBM Watson Health
  • Medidata Solutions Inc.
  • MedNet Solutions Inc.
  • Oracle Corporation
  • Parexel International Corporation
  • ArisGlobal

    Diagnostic Radiopharmaceuticals & Contrast Media Market 2019 report will help the industry aspirants in arranging their strategies. The measurements offered in this report will be an exact and helpful manual to shape the business development. Additionally, will Provide historical data along with a future forecast and detailed analysis and also expected opportunities.

    Scope of the Report:

  • Radiopharmaceuticals are a group of pharmaceutical drugs that have radioactivity and can be used as diagnostics and therapeutic agents. Contrast media is the substance used to enhance the contrast of an image, hence, making an image more detailed and apparent. Contrast media is increasingly being used in various medical imaging techniques, such as MRI and CT. This report analyzes and discusses the global radiopharmaceuticals and contrast media market.

    Reasons for Buying Diagnostic Radiopharmaceuticals & Contrast Media Market Report:

    • This report provides pin-point analysis for changing competitive dynamics
    • It provides a forward looking perspective on different factors driving or restraining market growth
    • It provides a five-year forecast assessed on the basis of how the market is predicted to grow
    • It helps in understanding the key product segments and their future
    • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
    • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/13999529

    Key Market Trends:

    Cardiology Sub-segment Captured the Largest Market Share and is Expected to Retain its Dominance

    The major factor driving the growth of the market is the rising prevalence of cardiovascular diseases over the world. According to the estimates of the World Health Organization (WHO), in 2016, 17.9 million people died from CVDs. SPECT, which stands for single photon emission computed tomography, is a non-invasive procedure that can accurately identify areas of abnormal myocardial perfusion. It is also used to determine the functional capacity of the heart muscle and is able to separate living tissue from an irreversibly damaged tissue. This diagnostic procedure helps physicians find out if there are blockages in the coronary (heart) arteries, as well as to determine if the patient should undergo a coronary angiogram. In SPECT, cardiac-specific radiopharmaceuticals, such as 99mTc-tetrofosmin (Myoview, GE healthcare), 99mTc-sestamibi (Cardiolite, Bristol-Myers Squibb), or Thallium-201 chloride are administered. Hence, factors, such as the rising prevalence of cardiovascular diseases and technological advancements in the field of diagnostics, are expected to drive the growth of the market over the forecast period.

    North America Captured the Largest Market Share and is Expected to Retain its Dominance

    North America dominated the overall diagnostic radiopharmaceuticals and contrast media market, with the United States accounting for the major contributor to the market. The US diagnostic radiopharmaceuticals and contrast media market is anticipated to continue its expansion over the forecast period. The first gadolinium-based contrast agent was approved in the United States. Four agents were approved in the United States in the past decade, and they have set a string trend in the industry to continue to find more efficient, accurate, and safe agents.

    The contrast media sales are expected to increase in the United States in the coming years. Among the different imaging modalities, sales of contrast media for the ultrasound market are likely to have a considerable growth rate. Diagnostic radioisotopes are a significant component of the US economy. Increase in chronic cardiac and neurological diseases is the primary driving factor for the market growth in the United States. Hence, the North American diagnostic radiopharmaceuticals and contrast media market is expected to retain its dominance over the forecast period.

    The Research Document Will Answer Following Questions Such as:

    • What are the cutting-edge technologies responsible for driving the growth of the market?
    • What are the main applications of the market? What are the growth prospects to the market applications into the market?
    • At what stage of development are the key market products?
    • What are the shortcomings that has to face to become commercially viable? Is their growth and commercialization dependent on cost declines or technological/application breakthroughs?
    • What is the outlook for the industry?
    • What difference does performance characteristics of Diagnostic Radiopharmaceuticals & Contrast Media create from those of established entities?

    Purchase this Report (Price 4250 USD for single user license) – https://www.industryresearch.co/purchase/13999529

    Detailed TOC of Diagnostic Radiopharmaceuticals & Contrast Media Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Market Drivers
    4.2.1 Technology Advancements in Medical Imaging
    4.2.2 Increasing Demand for Image-guided Procedures and Diagnostics
    4.2.3 High Prevalence of Cancers and Cardiac Diseases
    4.3 Market Restraints
    4.3.1 High Costs of the Techniques- Not Easily Affordable
    4.3.2 Limited Health Insurance Coverage
    4.3.3 Short Half-life of Radiopharmaceuticals
    4.4 Industry Attractiveness Porter’s Five Forces Analysis
    4.4.1 Threat of New Entrants
    4.4.2 Bargaining Power of Buyers/Consumers
    4.4.3 Bargaining Power of Suppliers
    4.4.4 Threat of Substitute Products
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 Radiopharmaceuticals
    5.1.1 By Type of Imaging Modality
    5.1.1.1 SPECT
    5.1.1.1.1 Tc-99
    5.1.1.1.2 Tl-201
    5.1.1.1.3 Ga-67
    5.1.1.1.4 I-123
    5.1.1.1.5 Other SPECTs
    5.1.1.2 PET
    5.1.1.2.1 F-18
    5.1.1.2.2 Rb-82
    5.1.1.2.3 Other PETs
    5.1.2 By Application
    5.1.2.1 Diagnostic Application
    5.1.2.1.1 SPECT Applications
    5.1.2.1.1.1 Cardiology
    5.1.2.1.1.2 Neurology
    5.1.2.1.1.3 Thyroid
    5.1.2.1.1.4 Other SPECT Applications
    5.1.2.1.2 PET Application
    5.1.2.1.2.1 Oncology
    5.1.2.1.2.2 Cardiology
    5.1.2.1.2.3 Neurology
    5.1.2.1.2.4 Other PET Applications
    5.1.2.2 Therapeutic Application
    5.1.2.2.1 Thyroid
    5.1.2.2.2 Lymphoma
    5.1.2.2.3 Endocrine Tumors
    5.1.2.2.4 Other Therapeutic Applications
    5.2 Contrast Media
    5.2.1 By Application
    5.2.1.1 Ionizing Radiation-based Radioimaging
    5.2.1.2 Non-Ionizing Radiation-based Radioimaging
    5.2.2 By Procedure
    5.2.2.1 X-ray/Computed Tomography (CT)
    5.2.2.1.1 Iodinated Contrast Media Ionic
    5.2.2.1.2 Iodinated Contrast Media Non-Ionic
    5.2.2.1.3 Barium-based Contrast Media
    5.2.2.2 Magnetic Resonance Imaging (MRI)
    5.2.2.2.1 Gadolinium-based Contrast Media
    5.2.2.2.2 Other Magnetic Resonance Imaging
    5.2.2.3 Ultrasound
    5.2.3 By Indication
    5.2.3.1 Cardiovascular Disease
    5.2.3.2 Oncology
    5.2.3.3 Gastrointestinal
    5.2.3.4 Disorders
    5.2.3.5 Neurological
    5.2.3.6 Disorders
    5.2.3.7 Other Indications
    5.3 Geography
    5.3.1 North America
    5.3.1.1 United States
    5.3.1.2 Canada
    5.3.1.3 Mexico
    5.3.2 Europe
    5.3.2.1 United Kingdom
    5.3.2.2 Germany
    5.3.2.3 France
    5.3.2.4 Italy
    5.3.2.5 Spain
    5.3.2.6 Rest of Europe
    5.3.3 Asia-Pacific
    5.3.3.1 China
    5.3.3.2 Japan
    5.3.3.3 India
    5.3.3.4 Australia
    5.3.3.5 South Korea
    5.3.3.6 Rest of Asia-Pacific
    5.3.4 Middle East & Africa
    5.3.4.1 GCC
    5.3.4.2 South Africa
    5.3.4.3 Rest of Middle East & Africa
    5.3.5 South America
    5.3.5.1 Brazil
    5.3.5.2 Argentina
    5.3.5.3 Rest of South America

    6 COMPETITIVE LANDSCAPE
    6.1 Company Profiles
    6.1.1 Bioclinica
    6.1.2 Bio-Optronics Inc.
    6.1.3 DATATRAK International Inc.
    6.1.4 ERT Clinical
    6.1.5 IBM Watson Health
    6.1.6 Medidata Solutions Inc.
    6.1.7 MedNet Solutions Inc.
    6.1.8 Oracle Corporation
    6.1.9 Parexel International Corporation
    6.1.10 ArisGlobal

    7 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Tuberculosis Diagnostics Market 2019 Industry Recent Developments, Size, Trends, Global Growth, Recent Developments and Latest Technology, Forecast Research Report 2024

    LCMS Market Size and Share 2019 | Global Industry Analysis By Trends, Future Demands, Growth Factors, Emerging Technologies, Prominent Players and Forecast Till 2026

    Tile Saw Market 2019 Share, Size, Regional Trend, Future Growth, Leading Players Updates, Industry Demand, Current and Future Plans by Forecast to 2023

    Raw Honey Market Current Status 2019 | Size, Share, Trend, Global Demand, Top Companies, Product Category and Forecast to 2023